Pharvaris N.V. (PHVS) vs SELLAS Life Sciences Group, Inc. (SLS)
A side-by-side comparison of Pharvaris N.V. and SELLAS Life Sciences Group, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
PHVS
Pharvaris N.V.
$30.92HealthcareDelayed quote: Oct 6, 2026, 3:05 PM EDT
SLS
SELLAS Life Sciences Group, Inc.
$11.45HealthcareDelayed quote: Oct 6, 2026, 3:05 PM EDT
Total return — PHVS vs SLS
growth of $100 · dividends reinvested · last 6yPHVS +5.1% (+0.8%/yr)SLS +90.6% (+11.4%/yr)SLS compounded faster over this window
PHVS SLS
PHVS vs SLS: by the numbers
- •PHVS is the larger company ($2.16B vs $2.13B market cap).
Metrics side by side
Valuation
| Metric | PHVS | SLS |
|---|---|---|
| P/B ratio | 6.29 | 15.47 |
Profitability
| Metric | PHVS | SLS |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% |
| ROE | -57.96% | -23.58% |
| ROIC | -61.74% | -25.45% |
Growth (annualized)
| Metric | PHVS | SLS |
|---|---|---|
| Total return CAGR (5Y) | 11.45% | 6.20% |
Frequently asked
- How have PHVS and SLS total returns compared?
- Over the past 5 years, PHVS delivered 11.45% and SLS delivered 6.20% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.